VEGFA and cancer: ABL001 (NOV1501/TR009), a bispecific antibody targeting VEGF and DLL4, is being developed as an anti-angiogenic cancer therapeutic that strengthens the effects of VEGF inhibitors and eventually overcomes resistance to anti-VEGF therapy [16,19,20,23].